Thrombosis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Thrombosis – Drugs In Development, 2023’, provides an overview of the Thrombosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Thrombosis
- The report reviews pipeline therapeutics for Thrombosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Thrombosis therapeutics and enlists all their major and minor projects
- The report assesses Thrombosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thrombosis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Thrombosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thrombosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Acticor Biotech SASAddpharma Inc
Alexion Pharmaceuticals Inc
Alfasigma SpA
Alphamab Oncology
Anthos Therapeutics Inc
Antibe Therapeutics Inc
Aplagon Oy
Apmonia Therapeutics SAS
APT Therapeutics Inc
Aronora Inc
Astellas Pharma Inc
Bayer AG
Beijing Kleb Pharmaceutical Development Co Ltd
Beijing Neoletix Biological Technology Co Ltd
Beth Israel Deaconess Medical Center
Bio-Synectics Inc
Bioxodes SA
Bristol-Myers Squibb Co
Cadrenal Therapeutics Inc
Calida Therapeutics
CarboMimetics
Catholic University of Leuven
Central Drug Research Institute
Cereno Scientific AB
Chengdu Shibeikang Biomedical Technology Co Ltd
China Biologic Products Holdings Inc
China Resources Emde Biological Pharmaceutical Co Ltd
China Resources Pharmaceutical Group Ltd
ChoDang Pharm Co Ltd
Chrysalis BioTherapeutics Inc
Cloud Pharmaceuticals Inc
CSL Ltd
CSPC Pharmaceutical Group Ltd
EVAS Therapeutics LLC
eXithera Pharmaceuticals Inc
FunPep Co Ltd
GLSynthesis Inc
Glycan Therapeutics Inc
Guangzhou Dazhou Biomedical Technology Co Ltd
Guangzhou General Pharmaceutical Research Institute Co Ltd
Guangzhou Recomgen Biotech Co Ltd
Hangzhou Adamerck Pharmlabs Inc
Harvard Medical School
HEC Pharma Co Ltd
Hefei Medical & Pharmaceutical Co Ltd
HKND YB1 Pharmaceutical Ltd
Indiana Lysis Technologies LLC
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangxi Jemincare Group Co Ltd
Jubilant Therapeutics Inc
Kalvista Pharmaceuticals Inc
KLUS Pharma Inc
Kolmar Korea Co Ltd
Laboratorios Farmaceuticos Rovi SA
Lee's Pharmaceutical Holdings Ltd
Lunac Therapeutics Ltd
Marizyme Inc
MDI Therapeutics Inc
Merck & Co Inc
Monash University
Mudanjiang Youbo Pharmaceutical Co Ltd
National Taiwan University
Nippon Shinyaku Co Ltd
North China Pharmaceutical Co Ltd
Oasis Pharmaceuticals LLC
Overseas Pharmaceuticals Ltd
Peel Therapeutics Inc
Protheragen Inc
Prothix BV
Quercis Pharma AG
R-Pharm
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Samjin Pharm Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Shenyang Pharmaceutical University
Shenzhen Salubris Pharmaceuticals Co Ltd
Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd
Shin Poong Pharm Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Signablok Inc
Sirius Therapeutics Inc
Sirnaomics Ltd
Southern Medical University
St. Vincent Hospital
Sujana Biotech
LLC
SupraGen LLC
Suzhou Ribo Life Sciences Co Ltd
Taho Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Targeted Therapeutic Solutions LLC
Techfields Pharma Co Ltd
The Hospital for Sick Children
Thomas Jefferson University
Tianjin Pharmaceuticals Group Co Ltd
Translational Sciences Inc
University of California Irvine
University of Colorado
University of Illinois at Chicago
University of Liege
University of North Carolina at Chapel Hill
University of Pennsylvania
University of Queensland
University of Sao Paulo
Veralox Therapeutics Inc
Verseon Corp
Virginia Commonwealth University
Vivozon Inc
X-37 LLC
Zehna Therapeutics LLC
Zerion Pharma AS
Zhejiang Hisun Pharmaceutical Co Ltd
Zonhon Biopharma Institute Inc